Martin R Berger Selected Research

Prostatic Neoplasms (Prostate Cancer)

12/2021	Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.
1/2019	ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin R Berger Research Topics

Disease

61	Neoplasms (Cancer) 12/2021 - 09/2003
39	Neoplasm Metastasis (Metastasis) 02/2021 - 09/2003
28	Colorectal Neoplasms (Colorectal Cancer) 04/2021 - 09/2003
18	Breast Neoplasms (Breast Cancer) 02/2021 - 12/2003
12	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 08/2005
7	Adenocarcinoma 01/2021 - 08/2005
7	Carcinoma (Carcinomatosis) 11/2012 - 06/2004
6	Leukemia 03/2014 - 08/2002
4	Squamous Cell Carcinoma of Head and Neck 01/2018 - 06/2012
3	Contracture 01/2021 - 02/2017
3	Disease Progression 05/2015 - 03/2005
3	Multiple Myeloma 03/2014 - 01/2007
3	Colonic Neoplasms (Colon Cancer) 03/2013 - 05/2005
3	Lymphatic Metastasis 03/2010 - 11/2007
2	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 01/2019
2	Inflammation (Inflammations) 12/2020 - 10/2014
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 12/2020 - 01/2014
2	Fibrosis (Cirrhosis) 01/2019 - 02/2017
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2018 - 01/2018
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2017 - 06/2012
2	Wounds and Injuries (Trauma) 10/2014 - 03/2014
2	Body Weight (Weight, Body) 11/2012 - 11/2003
2	Osteolysis 06/2012 - 05/2008
2	Chronic Pancreatitis 01/2007 - 08/2005
1	Immune System Diseases (Immune Disorders) 10/2021
1	Rare Diseases (Rare Disease) 12/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2019
1	Hematoma 01/2019
1	Melanoma (Melanoma, Malignant) 06/2016

Drug/Important Bio-Agent (IBA)

14	erucylphospho- N,N,N- trimethylpropylammoniumIBA 12/2021 - 08/2002
12	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 05/2005
10	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2004
9	LigandsIBA 10/2021 - 03/2005
9	Messenger RNA (mRNA)IBA 02/2021 - 11/2003
9	OsteopontinIBA 10/2019 - 02/2004
9	Integrin-Binding SialoproteinIBA 01/2018 - 02/2004
8	Chemokine ReceptorsIBA 01/2021 - 03/2005
6	Codon (Codons)IBA 07/2011 - 01/2004
5	Maraviroc FDA Link 04/2021 - 05/2015
4	Glycoproteins (Glycoprotein)IBA 10/2021 - 02/2004
4	IntegrinsIBA 02/2021 - 05/2011
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 01/2004
4	Gemcitabine FDA Link 02/2018 - 08/2002
4	ChemokinesIBA 02/2016 - 12/2006
4	SaporinsIBA 01/2016 - 09/2014
4	Fluorouracil (Carac)FDA LinkGeneric 03/2013 - 11/2003
3	Sepharose (Agarose)IBA 01/2021 - 01/2020
3	Carrier Proteins (Binding Protein)IBA 01/2021 - 01/2020
3	Collagenases (Collagenase)FDA Link 01/2021 - 02/2017
3	SiliconesIBA 01/2021 - 02/2017
3	CurcuminIBA 12/2020 - 01/2007
3	CC ChemokinesIBA 01/2020 - 05/2015
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 07/2011
3	Pharmaceutical PreparationsIBA 01/2018 - 06/2007
3	Small Interfering RNA (siRNA)IBA 02/2017 - 06/2012
3	Retinoblastoma ProteinIBA 01/2014 - 12/2003
3	OsteonectinIBA 07/2010 - 02/2004
3	Platelet-Derived Growth Factor alpha ReceptorIBA 03/2010 - 03/2008
2	ABT-737IBA 12/2021 - 01/2019
2	MicroRNAs (MicroRNA)IBA 02/2021 - 10/2019
2	LectinsIBA 01/2021 - 01/2020
2	Complementary DNA (cDNA)IBA 01/2021 - 02/2012
2	CCR5 Receptors (CCR5 Receptor)IBA 02/2019 - 05/2015
2	Capsules (Microcapsules)IBA 01/2019 - 11/2003
2	Chemokine CXCL12IBA 06/2016 - 03/2005
2	Biological ProductsIBA 05/2015 - 07/2011
2	PowdersIBA 11/2014 - 03/2006
2	LuciferasesIBA 12/2012 - 01/2010
2	Cisplatin (Platino)FDA LinkGeneric 06/2012 - 01/2007
2	CilengitideIBA 10/2011 - 05/2011
2	Transcription Factors (Transcription Factor)IBA 08/2010 - 11/2007
2	tyrosine receptor (receptor, tyrosine)IBA 03/2010 - 07/2007
2	Phosphotransferases (Kinase)IBA 03/2010 - 07/2007
2	beta-Galactosidase (Lactaid)IBA 01/2008 - 05/2005
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2008 - 04/2004
2	Antisense OligonucleotidesIBA 08/2005 - 08/2002
2	Keratin-20 (Cytokeratin 20)IBA 06/2004 - 11/2003
1	Cell Adhesion Molecule-1IBA 10/2021
1	Neuropilin-2IBA 10/2021
1	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 10/2021
1	Sialic AcidsIBA 10/2021
1	Galactose (Galactopyranose)FDA LinkGeneric 01/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2020
1	Endothelins (Endothelin)IBA 01/2020
1	SugarsIBA 01/2020
1	Decitabine FDA Link 01/2020
1	MethyltransferasesIBA 01/2020
1	Cadherins (E-Cadherin)IBA 01/2019
1	miltefosine (Impavido)IBA 01/2019
1	dinalineIBA 02/2018
1	Cyclin D1IBA 01/2018
1	CyclinsIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018

Therapy/Procedure

12	Therapeutics 02/2021 - 07/2007
3	Mammaplasty (Breast Reconstruction) 01/2021 - 02/2017
3	Injections 02/2017 - 08/2009
3	African Traditional Medicine (Medicine, African) 11/2014 - 03/2006
2	Castration 12/2021 - 01/2019
1	Antineoplastic Combined Chemotherapy Protocols 12/2021
1	Breast Implants (Breast Implant) 01/2021